---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-22-000054"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T01:02:38.869539+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Axogen Q1 rev flat at $31M, net loss widens to $0.20/sh; Avance Phase 3 hits endpoint

## Summary
- Net revenue $31.0M flat YoY; adjusted net loss $8.5M ($0.20/sh) vs $3.1M ($0.08) prior year.
- Cash and investments $73.7M at Mar 31, down from $90.3M at Dec 31, 2021.
- Phase 3 RECON study of Avance Nerve Graft met primary endpoint for sensory function; BLA submission planned H2 2023.
- Avance showed statistical superiority over conduits for gaps >12mm (p=0.021) and faster recovery (p=0.037).
- 2022 revenue guidance reaffirmed $135-142M; gross margin above 80%.

## SEC filing metadata
- accession: 0000805928-22-000054
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592822000054/0000805928-22-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592822000054/axgn-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-22-000054
- JSON: https://secwatch.observer/filing/0000805928-22-000054.json
- Plain text: https://secwatch.observer/filing/0000805928-22-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.